GlaxoSmithKline PLC ADR (GSK) is next scheduled to report earnings on Jul 28, 2026 (before market open). The consensus analyst EPS estimate for the upcoming quarter is $1.27.
Heading into this report, the model's fair value estimate sits 39.9% above the current price (model fair value differential above current price). Descriptive context only — not a forecast of the earnings result.
Equity Rank computed model fair value for GSK from 8 independent valuation methods with sufficient data. 8 place fair value above the current price of $51.80, and 0 place it below. The model-blended estimate lands at $72.45 — a model fair value differential of 39.9% above the current price under these model assumptions. The larger group corresponds to potential undervaluation versus the current price.
Equity Rank's fundamental strength composite scores GSK at 75.5/100 (B+, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at -5.5% per year and gross margin has moved +5.0 pp. Its SAVE composite score has moved -0.8 over the past 30 days.
GlaxoSmithKline PLC ADR (GSK) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator